A previous phase I clinical trial for patients with advanced solid tumors or lymphomas harboring MTAP deficiency showed that AG-270 effectively reduced SAM concentrations and SDMA levels in tumor cells, leading to a selective growth disadvantage in homozygous MTAP-deficient cancer cells (NCT03435250). This evidence concerns the gene MTAP and neoplasm.